Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 22;91(0):e1-e6.
doi: 10.4102/jsava.v91i0.2052.

Antimicrobial resistance patterns of Pseudomonas aeruginosa isolated from canine clinical cases at a veterinary academic hospital in South Africa

Ulemu L Eliasi  1 , Dikeledi Sebola, James W Oguttu, Daniel N Qekwana
Affiliations

Antimicrobial resistance patterns of Pseudomonas aeruginosa isolated from canine clinical cases at a veterinary academic hospital in South Africa

Ulemu L Eliasi et al. J S Afr Vet Assoc. .

Abstract

Although Pseudomonas aeruginosa (P. aeruginosa) can infect both animals and humans, there is a paucity of veterinary studies on antimicrobial resistance of P. aeruginosa in South Africa. Secondary data of canine clinical cases presented at the hospital from January 2007 to December 2013 was used. The following information was recorded: type of sample, the date of sampling and the antimicrobial susceptibility results. Frequencies, proportions and their 95% confidence intervals were calculated for all the categorical variables. In total, 155 P. aeruginosa isolates were identified and included in this study. All the isolates were resistant to at least one antimicrobial (AMR), while 92% were multi-drug resistant (MDR). Most isolates were resistant to lincomycin (98%), penicillin-G (96%), orbifloxacin (90%), trimethoprim-sulfamethoxazole (90%) and doxycycline (87%). A low proportion of isolates was resistant to imipenem (6%), tobramycin (12%), amikacin (16%) and gentamicin (18%). A high proportion of MDR-P. aeruginosa isolates was resistant to amoxycillin-clavulanic acid (99%), tylosin (99%), chloramphenicol (97%) and doxycycline (96%). Few (6%) of MDR-P. aeruginosa isolates were resistant to imipenem. Pseudomonas aeruginosa was associated with infections of various organ systems in this study. All P. aeruginosa isolates of P. aeruginosa exhibited resistance to β-lactams, fluoroquinolones and lincosamides. Clinicians at the hospital in question should consider these findings when treating infections associated with P. aeruginosa.

Keywords: Pseudomonas aeruginosa; antimicrobial resistance; dogs; multi-drug resistance; veterinary..

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alhazmi A., 2015, ‘Pseudomonas aeruginosa: Pathogenesis and pathogenic mechanisms’, International Journal of Biology 7(2), 44–67. 10.5539/ijb.v7n2p44 - DOI
    1. Ansari S., Dhital R., Shrestha S., Thapa S., Puri R., Chaudhary N. et al. , 2016, ‘Growing menace of antibacterial resistance in clinical isolates of Pseudomonas aeruginosa in Nepal: An insight of beta-lactamase production’, BioMed Research International 2016, 8, Article ID 6437208. 10.1155/2016/6437208 - DOI - PMC - PubMed
    1. Boyd M., Santoro D. & Gram D., 2019, ‘In vitro antimicrobial activity of topical otological antimicrobials and Tris-EDTA against resistant Staphylococcus pseudintermedius and Pseudomonas aeruginosa isolates from dogs’, Veterinary Dermatology 30(2), 139–e40. 10.1111/vde.12717 - DOI - PubMed
    1. Cabassi C.S., Sala A., Santospirito D., Alborali G.L., Carretto E., Ghibaudo G. et al. , 2017, ‘Activity of AMP2041 against human and animal multidrug resistant Pseudomonas aeruginosa clinical isolates’, Annals of Clinical Microbiology and Antimicrobials 16(1), 17 10.1186/s12941-017-0193-1 - DOI - PMC - PubMed
    1. Clinical and Laboratory Standards Institute , 2007, Performance standards for antimicrobial susceptibility testing: Seventeenth informational supplement, CLSI document M100-S17, Clinical and Laboratory Standards Institute; Wayne, PA.

MeSH terms

Substances

LinkOut - more resources